News | November 16, 2026

Lonza And CMS Sign License Agreement For NeuroPortal TfR1 Blood-Brain Barrier Technology

  • Lonza grants CMS global rights to newly acquired TfR1 technology in up to two neurodegenerative disease targets.
  • Lonza’s NeuroPortal TfR1 platform is designed to support effective delivery of biologics across the blood-brain barrier, with flexibility to tailor the approach to each therapeutic molecule.
  • This agreement marks the first license granted by Lonza for its newly acquired platform, providing CMS with development and commercial rights while retaining availability for licensing for other targets.

Lonza and China Medical System Holdings Limited (CMS) announced today a global exclusive license agreement for the use of Lonza’s NeuroPortal transferrin receptor 1 (TfR1) blood-brain barrier (BBB) technology in up to two products targeting neurodegenerative diseases. CMS is a pharmaceutical company, with headquarters in Hong Kong, focused on developing and commercializing specialty medicines, including treatments for central nervous system disorders.

The blood-brain barrier protects the brain, preventing many medicines from reaching this organ. This poses a major challenge for central nervous system (CNS) drug development. NeuroPortal TfR1 technology offers binding variants with different affinities, enabling developers to evaluate the balance between receptor engagement, transport across the barrier and brain exposure for their therapeutic molecule. The technology outperformed a leading industry benchmark in preclinical studies both when used as an IgG fusion and when combined with Lonza’s GlycoConnect platform. Together with Lonza’s expertise in protein expression, bioconjugation and developability, the platform offers customers a flexible approach to evaluating CNS delivery strategies.

CMS secured exclusive rights to the technology for the agreed product targets. In return, Lonza will receive an upfront payment, development and commercial milestones and royalties on net sales based on the agreement. Lonza will continue to offer licensing rights to NeuroPortal TfR1 technology for other therapeutic programs.

Peter Droc, Head of Licensing, Lonza, commented: “NeuroPortal TfR1 technology is designed to help optimize delivery of therapeutics to the brain, and gives developers flexibility to explore genetic fusion or bioconjugation approaches, tailoring the delivery strategy to the needs of their therapeutic molecule. Delivering therapeutic molecules that can cross the blood-brain barrier remains a critical challenge in the development of treatments for neurodegenerative diseases. In selecting this platform, CMS is marking an important step in the commercial development of this technology.”

Detailed results from Lonza’s NeuroPortal TfR1 platform will be presented at the 18th annual Protein & Antibody Engineering Summit (PEGS) in Lisbon, Portugal, from 16–19 November, highlighting the platform’s potential to support tailored delivery of therapeutic molecules across the BBB. To learn more about the platform, visit Blood-Brain Barrier.

About CMS
CMS is an innovative pharmaceutical company focused on the identification, building, and full lifecycle management of differentiated specialty pharmaceuticals. With a dual-engine approach of in-house R&D and collaborative R&D, and leveraging its core capability to build markets and brands from the ground up, CMS enables each medicine to fully realize both its clinical value and commercial value.

Focusing on unmet clinical needs, CMS efficiently advances the research, clinical development and regulatory approval of differentiated specialty medicines. Drawing on evidence-based medicine and long-standing expertise across specialty therapeutic areas, CMS establishes the medical positioning of its products. Through a professional academic promotion system, CMS drives clinical recognition and large-scale application of its products, translating clinical value into enduring brand competitiveness.

CMS focuses on specialty areas including cardiovascular-kidney-metabolic, central nervous system, gastroenterology, ophthalmology, and skin health. It continuously expands its product portfolio, fostering a tiered structure of marketed products and innovative pipeline candidates, and leverages its solid medical expertise and omni-channel commercialization network to drive the growth of new products. Dermavon, its skin health business, has grown into a leading innovative pharmaceutical company in China’s skin health sector. Meanwhile, CMS is expanding its international business with Southeast Asia as a base, advancing product introduction, registration and commercialization in line with local healthcare needs, while progressively optimizing its regional manufacturing footprint to strengthen localized operations and supply capabilities.

Source: Lonza